Pgr15l Inhibitors
Pgr15l inhibitors are a class of chemical compounds that interact specifically with a protein known as Pgr15l, which is encoded by a gene that has been identified and characterized in various biological studies. The name Pgr15l refers to a specific protein structure within a larger family of proteins, and the inhibitors designed to interact with this protein are crafted to bind to certain sites or domains of the protein, which in turn affects the protein's function. The exact nature of these inhibitors can vary widely, with some being small organic molecules, peptides, or even larger biomolecules. The design of such inhibitors is often based on detailed knowledge of the protein's shape and function, as well as the key regions of the protein that are critical for its activity.
The development of Pgr15l inhibitors is a complex process that involves a multitude of disciplines, including biochemistry, molecular biology, computational chemistry, and structural biology. Scientists employ various techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, or cryo-electron microscopy to determine the three-dimensional structure of Pgr15l. This structural information is crucial because it allows researchers to identify potential binding sites and understand the dynamic properties of the protein. Once potential binding sites are identified, chemical compounds are designed and synthesized to interact with these sites. The binding of inhibitors to Pgr15l can result in conformational changes to the protein's structure, which can affect the protein's function. Inhibition can occur through various mechanisms, such as blocking the active site, altering the protein's shape, or interfering with the protein's ability to interact with other molecules. The study of Pgr15l inhibitors is part of a broader field of research focused on elucidating the functions of proteins within cellular processes and understanding how these proteins can be modulated by specific compounds.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR. By inhibiting these kinases, imatinib can interfere with signaling pathways that contribute to the proliferation and survival of certain cells, potentially affecting downstream proteins such as Pgr15l by reducing proliferative signals. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that acts by binding to FKBP12 and the resultant complex inhibits mTORC1. This suppression of mTORC1 activity can downregulate protein synthesis and cell growth, which may indirectly reduce the functional activity of Pgr15l if it is regulated by mTOR-dependent signaling. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent, non-selective inhibitor of protein kinases. It can inhibit a wide range of kinases, potentially affecting the phosphorylation status of Pgr15l or its associated signaling proteins, leading to decreased activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that prevents the phosphorylation of AKT, thereby blocking the PI3K/AKT/mTOR pathway, which is involved in cell survival and growth. This inhibition may result in reduced activity or expression of Pgr15l if Pgr15l is implicated in this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the activation of MAPK/ERK. By inhibiting this pathway, PD98059 may reduce the expression or functional activity of Pgr15l if Pgr15l is involved in ERK-mediated signaling processes. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is a c-RAF inhibitor that impedes the RAS/RAF/MEK/ERK signaling pathway. Inhibition of this pathway can lead to decreased cell proliferation and differentiation, potentially reducing the activity of Pgr15l if it is downstream of this signaling cascade. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that targets multiple tyrosine protein kinases, such as VEGFR and PDGFR. It may impact signaling pathways that regulate cell proliferation and angiogenesis, potentially suppressing the activity of Pgr15l indirectly. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that interferes with the p38 MAPK pathway involved in stress responses, inflammation, and cell differentiation. By inhibiting this pathway, SB203580 may indirectly influence Pgr15l activity if Pgr15l functions are modulated by p38 MAPK activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the stress-activated MAPK pathway. Inhibition of JNK can affect apoptosis and inflammatory responses, possibly leading to decreased activity of Pgr15l if it is involved in JNK-mediated signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor with broad specificity, including BCR-ABL and SRC family kinases. Its action may alter various cellular processes, including adhesion, migration, and proliferation, which could indirectly decrease the activity of Pgr15l. | ||||||